181 related articles for article (PubMed ID: 24449433)
1. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.
Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
Med Decis Making; 2014 Apr; 34(3):387-402. PubMed ID: 24449433
[TBL] [Abstract][Full Text] [Related]
2. Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.
Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
Stat Methods Med Res; 2017 Apr; 26(2):724-751. PubMed ID: 25416688
[TBL] [Abstract][Full Text] [Related]
3. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
4. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
Latimer NR; White IR; Tilling K; Siebert U
Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
[TBL] [Abstract][Full Text] [Related]
5. A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
Latimer NR; Dewdney A; Campioni M
BMC Med Res Methodol; 2024 Jan; 24(1):17. PubMed ID: 38253996
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
Latimer NR; White IR; Abrams KR; Siebert U
Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
[TBL] [Abstract][Full Text] [Related]
8. Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting.
Sullivan TR; Latimer NR; Gray J; Sorich MJ; Salter AB; Karnon J
Value Health; 2020 Mar; 23(3):388-396. PubMed ID: 32197735
[TBL] [Abstract][Full Text] [Related]
9. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
Latimer NR; Abrams KR; Lambert PC; Morden JP; Crowther MJ
Stat Methods Med Res; 2018 Mar; 27(3):765-784. PubMed ID: 27114326
[TBL] [Abstract][Full Text] [Related]
10. Adjusting overall survival for treatment switches: commonly used methods and practical application.
Watkins C; Huang X; Latimer N; Tang Y; Wright EJ
Pharm Stat; 2013; 12(6):348-57. PubMed ID: 24136868
[TBL] [Abstract][Full Text] [Related]
11. Methods for adjusting for bias due to crossover in oncology trials.
Ishak KJ; Proskorovsky I; Korytowsky B; Sandin R; Faivre S; Valle J
Pharmacoeconomics; 2014 Jun; 32(6):533-46. PubMed ID: 24595585
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Evans R; Hawkins N; Dequen-O'Byrne P; McCrea C; Muston D; Gresty C; Ghate SR; Fan L; Hettle R; Abrams KR; de Bono J; Hussain M; Agarwal N
Target Oncol; 2021 Sep; 16(5):613-623. PubMed ID: 34478046
[TBL] [Abstract][Full Text] [Related]
13. TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES.
Latimer NR; Henshall C; Siebert U; Bell H
Int J Technol Assess Health Care; 2016 Jan; 32(3):160-6. PubMed ID: 27624982
[TBL] [Abstract][Full Text] [Related]
14. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
[TBL] [Abstract][Full Text] [Related]
15. Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching.
Bowden J; Seaman S; Huang X; White IR
Stat Med; 2016 Apr; 35(9):1423-40. PubMed ID: 26576494
[TBL] [Abstract][Full Text] [Related]
16. Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.
Latimer NR; Abrams KR; Amonkar MM; Stapelkamp C; Swann RS
Oncologist; 2015 Jul; 20(7):798-805. PubMed ID: 26040620
[TBL] [Abstract][Full Text] [Related]
17. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.
Latimer NR
Med Decis Making; 2013 Aug; 33(6):743-54. PubMed ID: 23341049
[TBL] [Abstract][Full Text] [Related]
19. Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.
Di Scala L; Bacchi M; Bayer B; Turricchia S
Adv Ther; 2022 Sep; 39(9):4346-4358. PubMed ID: 35917059
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
